Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.
Anthony D. Elias, MD
Advertisement
Articles by Anthony D. Elias, MD
Advertisement
Latest Updated Articles
Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast CancerPublished: August 4th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5